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Abstract
Steroid receptor activation in the developing brain influences a variety of cellular processes that endure into adulthood,
altering both behavior and physiology. Recent data suggests that dopamine can regulate expression of progestin receptors
within restricted regions of the developing rat brain by activating estrogen receptors in a ligand-independent manner. It is
unclear whether changes in neuronal activity induced by dopaminergic activation of estrogen receptors are also region
specific. To investigate this question, we examined where the dopamine D1-like receptor agonist, SKF 38393, altered Fos
expression via estrogen receptor activation. We report that dopamine D1-like receptor agonist treatment increased Fos
protein expression within many regions of the developing female rat brain. More importantly, prior treatment with an
estrogen receptor antagonist partially reduced D1-like receptor agonist-induced Fos expression only within the bed nucleus
of the stria terminalis and the central amygdala. These data suggest that dopaminergic activation of estrogen receptors
alters neuronal activity within restricted regions of the developing rat brain. This implies that ligand-independent activation
of estrogen receptors by dopamine might organize a unique set of behaviors during brain development in contrast to the
more wide spread ligand activation of estrogen receptors by estrogen.
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Introduction
Differential exposure to testosterone [1] and its metabolites [2]
during brain development leads to changes in neuronal survival,
neuronal migration, and the plasticity of both neurons and glia [3–
5] which underlie lasting sex differences in physiology and
behavior in many species. Altering steroid hormone levels during
the critical period for sexual differentiation [6–8] can impair
sexual differentiation. Steroid hormones produce many of these
transient and lasting changes within the brain by acting upon
intracellular steroid receptors. Not only are steroid receptors
themselves important in regulating brain differentiation, but the
additional factors, such as co-activators, recruited to the
transcriptional complex are equally important [9–11].
Recent evidence has shown that estrogen receptors (ERs) can also
be activated in the absence of ligand by a variety of neurochemical
compounds [12,13], including the neurotransmitter dopamine (DA)
[14]. We recently reported that dopamine appears to activate ER in
a ligand-independent manner within developing brain. Neonatal
treatment of female rats with a DA D1-like receptor agonist during
thefirstfewdaysoflifeincreasedlaterjuvenilesocialplaybehaviorto
male-like levels, and prior neonatal treatment with an ER antagonist
blocks dopamine-induced masculinization of social play [15],
suggesting that the effects of DA occur in part via ligand-
independent activation of ERs.
In addition to masculinizing the development of social play,
dopaminergic activation of ERs also increases the expression of the
ER-dependent progestin receptor (PR) within restricted brain
regions. Interestingly, neonatal treatment with the D1-like agonist
increased PR expression only within the central amygdala (CeA)
and the bed nucleus of the stria terminalis (BST) of the developing
female rat brain and these increases were blocked by an ER
antagonist [15], which is consistent with PR dependence upon ER
expression in developing brain [16]. We have also recently
reported that endogenous dopaminergic neurotransmission ap-
pears to play a role in regulating the normal expression of PR
within the neonatal rat brain. That is, DA D1-like receptor
antagonist treatment reduces PR expression within restricted brain
regions in neonatal male and female rats [17]. These data suggest
that DA can regulate PR expression within restricted regions of
developing brain. It is not known if other transcription factors
altered by ligand-independent activation of ERs exhibit a similar
region-specific pattern in developing brain.
One transcription factor known to be regulated by steroid
receptor activity is c-fos, which codes for Fos protein. Testosterone,
estradiol, and progesterone, but not 5a-dihydrotestosterone,
increase Fos protein expression in the developing and adult brain
[18–22]. Additionally, males express more Fos protein compared
to females within some sexually dimorphic brain regions during
brain development [23]. Fos protein expression can also be up-
regulated by neurotransmitters, such as DA [24], non-steroid
hormones, such as oxytocin [25], and a variety of physical stimuli
[26,27]. As changes in Fos expression can be used as an indicator
of changes in cellular activity, Fos protein provides a useful tool for
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steroid receptor activation [28]. We have previously used Fos as a
marker to identify where ligand-independent activation of PRs
occurs in the brain following social interaction [29]. Although it is
known that estradiol [18,21] and DA [30] increase Fos expression
within some regions of the developing female brain, it is not known
whether dopaminergic activation of ERs can alter Fos protein
expression in the developing brain. In experiment 1, we examined
if a D1-like receptor agonist can induce Fos expression with brain
regions that respond to dopaminergic activation of ERs (i.e. the
bed nucleus of the stria terminalis (BST) and central amygdala
(CeA)). In experiment 2, we tested if the DA D1-like receptor
agonist-induced Fos expression within the developing female rat
brain could be blocked by ER antagonist treatment.
Methods
Animals
Adult female Sprague Dawley rats (Charles River Laboratories,
Inc., Wilmington, MA) were mated in our animal facility and
allowed to deliver normally. Cages were checked regularly to
determine the day of birth. This research was approved by the
University of Wisconsin Animal Care and Use Committee.
Experiment 1: Within which brain regions does DA D1-
like receptor agonist treatment induce Fos expression?
Neonatal female rats (n=3–4 per group) were subcutaneously
injected with either 100 mg of the DA D1-like receptor agonist,
SKF 38393, or vehicle on the day after birth (postnatal day 1;
PN1). This dose of SKF 38393 has been previously shown to
activate ERs within the developing rat brain to increase PR
expression and social play behavior [15]. Animals were sacrificed
by rapid decapitation without anesthesia 2.5 h later. Brains were
collected and immediately immersed in 5% acrolein for 24 h at
4uC then placed in 0.1 M TBS containing 30% sucrose at 4uC
until infiltrated. Brains were sectioned coronally at 40 mm using a
cryostat at 220uC and stored in cryoprotectant at 220uC until
processed for Fos immunocytochemistry.
Experiment 2: Within which brain regions does an
estrogen receptor antagonist block SKF 38393-induced
Fos expression?
On PN1 neonatal female rats were subcutaneously injected with
either 100mg of the pure ER antagonist, PSK 3668 (formerly RU
58668, ProSkelia SASU, a Galapagos company), or vehicle, then
2 h later with either 100mg of the DA D1-like receptor agonist,
SKF 38393, or vehicle (Veh+Veh n=7; Veh+SKF n=8;
PSK+Veh n=6; PSK+SKF n=9). PSK 3668 was used because
it appears to lack partial agonist properties [31,32] and crosses the
blood-brain barrier [33]. We conducted pilot studies that confirm
that the dose of PSK 3668 used in these experiments does not
increase PR expression, a marker of ER activity, within the
developing brain. PSK 3668 also has a higher binding affinity for
ER than tamoxifen and is more potent than both tamoxifen and
ICI 182, 780 [31]. PSK 3668 administered systemically blocks ER
binding [33] and ER-induced PR expression [34] in the adult rat
brain, as well as female sexual behavior [32]. The dose and timing
of PSK 3668 was chosen based on pilot tests indicating that 100mg
2 h prior to estradiol treatment was sufficient to block estradiol-
induced PR expression in the neonatal female rat brain.
Additionally, previous studies indicate that treatment with this
dose of another ER antagonist, tamoxifen, 2h prior to SKF 38393
treatment is sufficient to block the effects of dopaminergic
activation of ER on PR expression and social play behavior
[15]. Animals were sacrificed by rapid decapitation without
anesthesia 2.5 h after the second injection. We believe that 2.5 h is
sufficient for the D1 agonist to induce Fos expression via ER
dependent pathways, as vaginocervical stimulation is able to induce
Fos expression via dopaminergic activation of PR [35] within 1h
[36]. Brains were collected and immediately immersed in 5%
acrolein for 24 h at 4uC then placed in 0.1 M TBS containing 30%
sucrose at 4uC until infiltrated. Brains were sectioned coronally at
40 mmu s i n gac r y o s t a ta t220uC and stored in cryoprotectant at
220uC until processed for Fos immunocytochemistry.
Fos immunocytochemistry
Sections were washed three times for 5 min each in 0.1 M TBS
(pH 7.4) then placed in 0.1% sodium borohydride for 15 min.
Sections were then washed three times for 5 min each in TBS and
placed in TBS containing 1% H2O2 and 20% normal goat serum
for 1 hour to reduce endogenous peroxidase activity and nonspecific
staining.SectionswerethenincubatedinFosantibody(cat# SC-52,
1:2000 dilution, Santa Cruz Biotechnology, Santa Cruz, CA)
overnight at room temperature in TBS containing 0.3% Triton X-
100 (TTBS), 2% normal goat serum, and 0.5% gelatin. Following
primary incubation, sections were washed 3 times for 5 min each in
TTBSandthenincubatedinbiotinylatedgoatanti-rabbitIgG(cat#
BA-1000, 1:500 dilution, Vector Laboratories, Burlingame, CA) for
90 min at room temperature. Sections were then washed three times
for 5 min each in TTBS and two times for 5 min each in TBS.
Following washes, sections were incubated in VectastainABC (cat #
PK-6100, 1:400 dilution, Vector Laboratories, Burlingame, CA) for
1h. Sections were rinsed three times for 5 min each in TBS then
treated with Vector SG (cat # SK-4700, 1:167 dilution, Vector
Laboratories, Burlingame, CA) for 10 min. Developed sections were
mounted on gelatin-coated slides and coverslipped using Permount
mounting medium. Omission of Fos primary eliminated all
immunoreactivity.
Computer-aided image analysis
One section per brain region was matched according to the rat
brain atlas of Paxinos and Watson [37] and the neonatal rat brain
atlasbyAltmanandBayer[38].PlatenumbersfromthePaxinosand
Watson [37] atlas used to match each region are indicated below.
Bilateral counts were made and summed on closely matched
sections. Matching and counting was performed by an experimenter
blind to treatment condition. Fos protein expression was quantified
in a variety of sexually dimorphic and ER containing brain nuclei,
including the anteroventral periventricular nucleus (AVPV, plate
18), BST (plate 19), medial preoptic area (mPOA, plate 21), CeA
(plate 28), ventromedial hypothalamus (VMH, plate 30), arcuate
nucleus(Arc, plate30),and habenula(Hb,plate 33). Areaswhichare
not sexually dimorphic and do not contain ERs, including the
caudate putamen (CPu, plate 21), and posterior periventricular
thalamic nucleus (PVP, plate 33) were also examined.
Bilateral counts of Fos-immunoreactive cells were obtained using
an Olympus BX61 microscope fitted with an Olympus FV II digital
camera, connected to a PCcompatible computer. The software used
for analysis was Olympus MicroSuite (Soft Imaging System Corp.,
Lakewood, CO). Thresholds to detect foreground were set
independently for each measurement to account for possible
variability in background staining. The threshold was determined
automatically by the imaging software, and was approximately 3
standard deviations greater than the gray value mean of the
background staining. Particles with gray values greater than the
thresholdweredetectedusingtheparticledetectionsettingwithinthe
Olympus MicroSuite software program. We have used this method
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mean background routinely with great success [15,17,23]. Data for
each brain region were analyzed separately with two-tailed Student
t-tests (Experiment 1) or two-way ANOVAs with Tukey post-hoc
tests (Experiment 2) using the SigmaStat Statistical Analysis System
3.1 software (Jandel Scientific, Corta Madera, CA).
Results
Experiment 1: Within which brain regions does DA D1-
like receptor agonist treatment induce Fos expression?
SKF 38393-treated animals expressed increased Fos compared
to control animals within most of the regions examined. SKF
38393 increased the number of Fos-immunoreactive cells within
the AVPV, CPu, BST (Fig 1, 2), mPOA, CeA, VMH, Arc, and Hb
(df=5, p#0.002 for all regions). These results are consistent with
previous reports suggesting that SKF 38393 treatment increases
Fos expression within the CPu, VMH, and Hb of fetal rats [30], as
well as within the mPOA, VMH, and Arc of estradiol primed
adult female rats [24] and the CeA of adult male rats [39]. In
contrast, SKF 38393-treated animals did not express more Fos
compared to control animals within the PVP (df=5, p.0.05).
Experiment 2: Within which brain regions does an
estrogen receptor antagonist block SKF 38393-induced
Fos expression?
As expected, SKF 38393 increased Fos expression within most
regions. SKF 38393-treated animals expressed more Fos immu-
noreactive cells compared to control animals within the AVPV,
CPu, BST (Fig 3, 4), mPOA and CeA (F(1,26),p ,0.001), as well as
within the VMH, Arc , and Hb (F(1,24),p ,0.001). SKF 38393 did
not alter Fos expression within the PVP (F(1,26),p .0.05). The
effect of PSK 3668 on Fos expression appeared to be region
specific, as PSK 3668 reduced Fos expression only within the BST
and CeA (F(1,26),p ,0.05). In contrast, Fos expression was
unaltered by PSK 3668 within the AVPV, CPu, mPOA (Fig 5)
and PVP, as well as within the VMH, Arc, and Hb (p.0.05).
Interactions between PSK 3668 and SKF 38393 treatment were
found only within the BST and CeA (F(1,26),p ,0.001). Posthoc
testing indicates that within these regions, SKF 38393 increased
Fos expression in both vehicle (p,0.001) and PSK3668-treated
animals (p,0.001). SKF 38393-induced Fos expression was
partially reduced by prior treatment with PSK 3668 within the
BST and CeA (p,0.001); however, PSK 3668 did not alter Fos
expression in vehicle-treated animals within these regions
(p.0.05). Although somewhat surprising, these results are
consistent with previous reports that dopaminergic activation of
estrogen receptors altered PR expression only within the BST and
Figure 1. Effect of SKF 38393 on Fos expression within the
developing female rat brain. SKF 38393 increased Fos expression
within the AVPV, CPu, BST, mPOA, CeA, VMH, Arc, and Hb, but not
within the PVP. Data are shown as mean6standard error. * indicates
p,0.05.
doi:10.1371/journal.pone.0002177.g001
Figure 2. SKF 38393-induced Fos expression within the BST and mPoA. Photomicrographs of SKF 38393-induced Fos expression within the
BST and mPOA. The right column shows schematics of the regions pictured. Shaded area indicates regions examined. 3V, third ventricle; ac, anterior
commissure; BST, bed nucleus of the stria terminalis; LV, lateral ventricle; mPOA, medial preoptic area.
doi:10.1371/journal.pone.0002177.g002
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within any brain region.
Discussion
To examine where DA acts in an ER-dependent manner within
thedevelopingbrain,wefirstusedimmunocytochemistrytoexamine
where stimulation of DA D1-like receptors increased Fos expression
in the neonatal female rat brain. Treatment with the DA D1-like
receptor agonist, SKF 38393, increased Fos expression within the
AVPV, CPu, BST, mPOA, CeA, VMH, Arc, and Hb. These results
are consistent with previous reports of SKF 38393-induced Fos
expression within the fetal [30] and adult rat brain [24,39]. To
determine whether the SKF 39393-induced increase in Fos
expression is mediated in part by ER activity, we examined the
pattern of SKF 38393-induced Fos expression in neonatal female
rats in the presence or absence of the ER antagonist, PSK 3668.
While SKF 38393 increased Fos expression in many regions of
neonatal rat brain, we found that SKF 38393-induced Fos
expression was partially blocked by PSK 3668 only within the
BST and CeA. These data are consistent with our previous findings
indicating that ERs mediate DA action inthe developing rat brainto
alter PR expression only withinrestricted brainregions [15,17]. This
suggests that ERs located within the BST and CeA can mediate the
actions of DA D1-like receptor activation to alter gene expression.
The lack of Fos induced by ER-mediated DA action outside of
the BST and CeA does not necessarily indicate that DA does not
act via ERs in other brain regions. It is possible that ERs mediate
the effects of DA in other brain regions without resulting in Fos
expression; however, regulation of PR by ER-mediated DA action
is also limited to the BST and CeA [15], suggesting that
dopaminergic action may be mediated by ERs only within these
regions. This would not imply that other regions are insensitive to
activation of ERs by other factors. Factors other than DA, such as
epidermal growth factor [40–42] and insulin-like growth factor-1
[41,43–45], have been found to activate ERs both in vitro and in
vivo. It is possible that regions which appear to be insensitive to
ER-mediated DA action may be sensitive to activation of ERs by
these growth factors.
The region specific induction of Fos by ER-mediated DA action
in developing brain appears to be correlated with the distribution
of dopaminergic innervation. Although little is known about the
ontogeny and distribution of D1 receptors in the neonatal rat
brain, D1 receptor distribution within the adult rat brain has been
characterized. While D1 receptors are found within the BST,
mPOA, CeA, VMH, Arc, Hb, and CPu in adult rats [46–49],
SKF 38393-induced increases in Fos are reduced by PSK 3668
only within the BST and CeA. Interestingly, this pattern correlates
with the expression in the adult rat brain of the DA D1 receptor
marker, DARPP-32, a DA and cAMP regulated phosphoprotein,
which is found primarily within cells containing DA D1 receptors
[50]. DARPP-32 is expressed at high levels within the BST and
CeA with lower levels of DARPP-32 immunoreactivity within the
mPOA and VHM [51]. The BST and CeA also express more DA
D1 receptors and tyrosine hydroxylase (TH) immunoreactivity
than the mPOA or VMH in adulthood [46,47]. As TH is involved
in the synthesis of DA, these data indicate that the BST and CeA
Figure 3. Effect of PSK 3668 on SKF 38393-induced Fos
expression. SKF 38393 increased Fos expression within the AVPV,
CPu, BST, mPOA, CeA, VMH, Arc, and Hb, but not within the PVP.
Pretreatment with PSK 3668 partially blocked SKF 38393-induced Fos
expression within the BST and CeA. Data are shown as mean6standard
error. Within each brain region, bars not denoted by the same letter are
statistically different (p,0.05).
doi:10.1371/journal.pone.0002177.g003
Figure 4. Photomicrographs of SKF 38393-induced Fos expres-
sion partially blocked by PSK 3668 within the bed nucleus of
the stria terminalis. A schematic of this region is shown in Figure 2.
ac, anterior commissure; LV, lateral ventricle.
doi:10.1371/journal.pone.0002177.g004
Figure 5.Photomicrographs of SKF 38393-induced Fos expres-
sion within the mPOA. PSK 3668 did not block SKF 38393-induced
Fos expression within this region. A schematic of this region is shown in
Figure 2. 3V, third ventricle.
doi:10.1371/journal.pone.0002177.g005
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Taken together, these data suggest that ER-containing cells within
the BST and CeA may be more sensitive to DA than those within
the mPOA and VMH.
It is unlikely that changes in gonadal steroid hormone secretion
contributed to the SKF 38393-induced increase in Fos expression.
We have previously demonstrated that treatment with the same dose
of SKF 38393 did not alter serum estradiol concentrations in
neonatal female rats [15]. Furthermore, previous studies suggest that
the neonatal ovary is not actively producing steroid hormones at the
timepoint examined[52,53].If SKF 38393 increased Fos expression
by increasing peripheral estradiol secretion, then we would expect a
more generalized reduction of SKF 38393-induced Fos expression
by the ER antagonist, PSK 3668; however, SKF 38393-induced Fos
expression is reduced by PSK 3668 only within the BST and CeA. It
is important to note that we cannot exclude the possibility that SKF
38393 or PSK 3668 altered local synthesis of estradiol within the
BST and CeA, but not within the other regions examined. Recent
evidence indicates that estradiol synthesis can occur within the
developing rat brain [2], particularly within the hippocampus,
suggesting that it may be possible for SKF 38393 or PSK 3668 to
alter local estradiol synthesis in a region-specific manner, such as the
BST and CeA but not the mPOA or hypothalamus.
The incomplete blockage of SKF 38393-induced Fos by PSK
3668 suggests that SKF 38393 induces Fos by both ER-dependent
and ER-independent pathways. While it is expected that SKF
38393 alters Fos expression via ER-independent pathways, it is not
known if SKF 38393 alters Fos expression via activation of other
steroid receptors during brain development. For example, PRs are
expressed within the BST and CeA [15,54] and are activated by
DA or D1-like receptor agonists in vitro [14] and in adult female rat
brain [55].
The mechanisms by which SKF 38393 may alter ER activity to
increase Fos expression are currently unclear. The literature
suggests that intracellular signaling pathways activated by D1-like
receptor binding may phosphorylate or alter the conformation of
steroid receptors or other proteins involved in the transcriptional
complex, such as coactivators, thus allowing transcriptional
activity (see Blaustein, 2004 and Auger, 2004 for review). In vitro
evidence suggesting that dopaminergic activation of ERs can be
blocked by an inhibitor of the PKA pathway [56] supports this
hypothesis; however, it is unclear if the PKA pathway is necessary
for DA to alter ER activity within the developing brain. It is also
unclear if D1-like receptor activity alters ER activity directly or
indirectly. While it is possible that D1-like receptor activity alters
the activity of ERs within the same cell, it is also plausible that D1-
like receptor activity may influence ER activity within other cells
by altering the release of growth factors such as epidermal growth
factor and insulin-like growth factor-1, which activate ERs in
ligand-independent manner in vitro and within the adult female rat
brain [40,41,43]. Additionally, dopamine may act upon ER
containing cells to indirectly alter Fos expression, via efferent
pathways, in cells that do not express ERs.
As our previous research indicates that D1-like receptor
activation of ERs can alter expression of the sexually dimorphic
PR protein [15,17], it is possible that ER-mediated dopaminergic
activity may contribute to sex differences in protein expression
during brain development. Previous research has suggested that
neonatal males express more Fos protein compared to females
within developing BST and CeA [23]. The ability of PSK 3668 to
block SKF 38393-induced Fos within these regions suggests that
ER-mediated DA action might contribute to sex differences in Fos
expression within the BST and CeA.
Behaviorally, ER is important for the defeminization of sexual
behavior [57] and masculinization of juvenile social play [15].
While it is unclear how ER activity specifically within the BST and
CeA are likely to impact behavior, the BST is implicated in sexual
behavior [58], and the CeA in juvenile social play [59] suggesting
that these behaviors may be altered by ER-mediated DA action
within the BST and CeA. Our previous data indicate that juvenile
social play is masculinized by ER-mediated DA action in
developing brain [15]; however, it remains to be determined if
this is due to ER activity specifically within the BST and CeA.
The functional significance of multiple pathways to activate ERs
is unclear. One possibility is that estrogenic and dopaminergic
pathways are functionally distinct. In vitro evidence suggesting
differential ER degradation following estradiol and PKA activa-
tion [60] supports this idea. Our previous data indicate that
dopaminergic regulation of PR protein occurs only in brain
regions where PR expression is sexually monomorphic and
estrogen-insensitive [15,17], suggesting functional distinction of
these pathways in vivo, as well. Alternately, dopaminergic
activation may provide a mechanism by which environmental
stimuli that alter dopaminergic activity may influence protein
expression and/or sexual differentiation of brain and behavior.
Nonetheless, these data contribute to the idea that DA
transmission can influence ER-mediated sexual differentiation of
the brain in a region specific manner. They also suggest that
hormonal, social, or environmental factors that alter DA activity
during brain development might have lasting consequences on
brain and behavior via altering the activity of ER.
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